Neoplastic Lesions of the Pancreas

  • H.G. Beger
  • M. Siech


Most of the patients suffering from pancreatic cancer complain about upper abdominal pain, back pain, weight loss and change of bowel movements. The following signs and symptoms are suspected to be caused by pancreatic cancer: weight loss and back pain in the lower spinal column managed by orthopedic measures without improvement, upper abdominal pain continuing after cholecystectomy and unexplained abnormal glucose tolerance. Patients in cancer stage UICC I+II have survival benefits from oncological resection. However many patients are diagnosed in a very advanced stage with metastasation and/or cancer infiltration into retropancreatic vessels and the mesentery of the small and large bowel. Subgroups of patients with unresectable cancer have benefits from palliative chemotherapy and continuous pain management in regard to maintenance of quality of life and prolongation of survival.


Pancreatic Cancer Chronic Pancreatitis Cystic Tumor Advanced Pancreatic Cancer Mucinous Cystic Neoplasm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DiMagno EP, Reber HA, Tempero MA (1999) American Gastroenterological Association Médical Position Statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117;1463–1484CrossRefGoogle Scholar
  2. 2.
    Lowenfels AB, Maisonneuve P, Cavallini G et al (1993) Pancreatitis and the risk of pancreatic cancer. N Engl J Med 328; 1433–1437PubMedCrossRefGoogle Scholar
  3. 3.
    Ghane P, Katscha A, Evans JD, Neoptolemos P, Molecular prognositic markers in pancreatic cancer. (2002) J Hepatobiliary Pancreat Surg 9; 1–11CrossRefGoogle Scholar
  4. 4.
    Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, Beger H (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin Invest 90; 1352–1360PubMedCrossRefGoogle Scholar
  5. 5.
    Gansauge F, Gansauge S, Schmidt E, Müller J, Beger HG (1998) Prognostic significance of molecular alterations in human pancreatic carcinoma — an immunohistological study. Langenbeck’s Arch Surg 383; 152–155Google Scholar
  6. 6.
    Rozenblum E, Schutte M, Goggins M (1997), Tumor suppressor pathways in pancreatic carcinoma. Cancer Res 57; 1731–1734PubMedGoogle Scholar
  7. 7.
    Friedrich J M (1996) Computed tomography and magnetic resonance imaging in pancreatic cancer. In: Diagnostic procedures in pancreatic diseases Ed. P. Malfertheimer et al., Springer p 349–357Google Scholar
  8. 8.
    Fernandez-Castillo C, Rattner DW, Warshaw AL (1998) Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 82; 1127–1129CrossRefGoogle Scholar
  9. 9.
    Tsuchiya R, T Noda, N Harada et al (1986) Collective review of small carcinomas of the pancreas. Ann Surg. 203; 77–82PubMedCrossRefGoogle Scholar
  10. 10.
    Gudjonsson B (1996) Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the west Midlands: an epidemiological study. Br J Surg 83; 874PubMedCrossRefGoogle Scholar
  11. 11.
    Pitt H, Gomes A, Luis JF (1985) The preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surgery 201, 545–553CrossRefGoogle Scholar
  12. 12.
    Sohn TA, Lillemoe KD, Cameron JL et al (1999) Surgical palliation of unresectable periampullary adenocarcinoma. J Am Coll Surg 188; 658–669PubMedCrossRefGoogle Scholar
  13. 13.
    Peitralina A, Vistoli F, Carobbi A et al (2000), Thoracoscopic splanchnicectomy for pain relief in unresectable pancreatic cancer. Arch Surg 135; 332–335CrossRefGoogle Scholar
  14. 14.
    Stornioli AM, Enas NH, Brown Ca et al (1999) An investigational new drug treatment program for patients with gemcitabine. Cancer 85; 1261–1268CrossRefGoogle Scholar
  15. 15.
    Okada S, Sataka Y, Matsuno S et al (1999) Phase II study of docetaxel in patients with metastatic pancreatic cancer. Br J Cancer 80; 438–443PubMedCrossRefGoogle Scholar
  16. 16.
    Cascim S, Frontini L, Cornelia G et al (1999) Intensive weakly chemotherapy is not effective in advanced pancreatic cancer patients. Br J Cancer 79; 491–494CrossRefGoogle Scholar
  17. 17.
    Nukui Y, Picozzi VJ, Traverso LW (2000) Interferon based adjuvant chemoradiation therapy improves survival after pancreaticoduo-denectomy for pancreatic cancer. Am J Surg 179; 367–371PubMedCrossRefGoogle Scholar
  18. 18.
    Scheithauer W, Kornek GV, Raderer M et al (1999) Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic cancer. Br J Cancer 80; 1797–1802PubMedCrossRefGoogle Scholar
  19. 19.
    Snady H, Bruckner H, Copermann A, Paradiso D, Kiefer L (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. Cancer 89: 314–327PubMedCrossRefGoogle Scholar
  20. 20.
    Compagno J, Oertel JE. (1978) Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). AM J Clin Pathol; 69: 573–580PubMedGoogle Scholar
  21. 21.
    Compagno J, Oertel JE. (1978) Microcystic adenomas of the pancreas (glycogen-rich cystadenomas). Am J Clin Pathol, 69: 289–298PubMedGoogle Scholar
  22. 22.
    Klöp pel G, Solcia E, Longnecker DS, et al. Histological typing of tumors of the exocrine pancreas. In: World Health Organization International Histological Classification of Tumours. 2nd ed. Springer, Berlin Heidelberg New York; 1996; 11–20Google Scholar
  23. 23.
    Warshaw AL, Compton CC, Lewandrowski K, Cardenosa G, Mueller PR. Cystic tumors of the pancreas: new clinical, radiologic, and pathologic observations in 67 patients. Ann Surg 1990; 212: 432–445PubMedCrossRefGoogle Scholar
  24. 24.
    Siech M, Tripp K, Schmidt-Rohlfing B, Mattfeldt T, Widmaier U, Gansauge F, Gorich J, Beger H G. (1998) Cystic tumours of the pancreas: diagnostic accuracy, pathologic observations and surgical consequences, Langenbecks Arch Surg, 383: 56–61PubMedCrossRefGoogle Scholar
  25. 25.
    Warshaw AL, Compton CC, Lewandrowski K, Cardenosa G, Mueller PR. (1990) Cystic tumors of the pancreas: new clinical, radiologic, and pathologic observations in 67 patients. Ann Surg; 212: 432–445PubMedCrossRefGoogle Scholar
  26. 26.
    Obara T, Maguchi H, Saitoh Y, Ura H, Koike Y, Kitazawa S, Namiki M. (1991) Mucin-producing tumor of the pancreas: a unique clinical entity. Am J Gastroenterol; 86: 1619–1625PubMedGoogle Scholar
  27. 27.
    Bartley O, Ekdahl PH, Hulten L. (1966) Paraganglioma simulating pancreatic cyst. Acta Chir Scand; 132: 289–297PubMedGoogle Scholar
  28. 28.
    Frantz VK (1959) Tumor of the pancreas. In: Hartmann WH (ed) Atlas of tumor pathology. VII, fascicles 27 and 28. Armed Forces Institute of Pathology, Washington, DC, p 32Google Scholar
  29. 29.
    Siech M, Merkle E, Mattfeldt T, Widmaier U, Brambs HJ, Beger HG. (1996) Solid-pseudopapilläre Tumoren des Pankreas; Chirurg, 67: 1012–1015Google Scholar
  30. 30.
    Skogseid B, Eriksson B, Lundqvist G, Lorelius LE, Rastad J, Wide L, Akerstrom G, Oberg K. (1991) Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrin Metab 73: 281–287CrossRefGoogle Scholar
  31. 31.
    Zollinger RM, Ellison EH. (1955) Primary peptic ulcération of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142: 709–728PubMedCrossRefGoogle Scholar
  32. 32.
    Gregory RA, Tracy HJ, French JM, Sirus W. (1960) Extraction of a gastrinlike substance from a pancreatic tumor in a case of Zollinger-Ellison syndrome. Lancet i: 1045–1048CrossRefGoogle Scholar
  33. 33.
    Ellison EH, Wilson SD. (1964) The Zollinger-Ellison syndrome: reappraisal and evaluation of 260 registered cases. Ann Surg 160: 512–530PubMedCrossRefGoogle Scholar
  34. 34.
    Wolfe MM, Jensen RT. (1987) Zollinger-Ellison syndrome, current concepts in diagnosis and management. N Engl J Med 317: 1200–1209PubMedCrossRefGoogle Scholar
  35. 35.
    Meko JB, Norton JA. Gastrinoma. In: The Pancreas, edited by Beger HG, Warshaw AL, Büchler MW, Carr-Locke DL, Neoptolemos JP, Russell C, Sarr MG; (1998) Vol. 2, Blackwell science, p 1228–1253Google Scholar
  36. 36.
    Norton JA. (1994) Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 31:77–164PubMedCrossRefGoogle Scholar
  37. 37.
    Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, Polak JM, Hacki WH, Stamm B, Heitz PU. (1990) Duodenal gastrinomas as the source of hypergastrinemia and Zollinger-Ellison syndrome in patients with MEN-I. N Engl J Med 322: 723–727PubMedCrossRefGoogle Scholar
  38. 38.
    Arnold R, Frank M, Bül chmann G. Insulinoma and persistent neonatal hyperinsulinemic hypoglycemia (nesidioblastosis). In: The Pancreas, edited by Beger HG, Warshaw AL, Büchler MW, Carr-Locke DL, Neoptolemos JP, Russell C, Sarr MG. Vol. 2, Blackwell science, 1998; p 1187–1202Google Scholar
  39. 39.
    van Heerden JA, Edis AJ, Service FJ. (1979) The surgical aspects of insulinomas. Ann Surg 189: 677–682PubMedCrossRefGoogle Scholar
  40. 40.
    McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108: 1091–109PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • H.G. Beger
    • 1
  • M. Siech
    • 1
  1. 1.Chirurgische Universitätsklinik u. PoliklinikUniversität UlmUlmGermany

Personalised recommendations